We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

94 hedge funds and large institutions have $74.8M invested in TCR2 Therapeutics Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 36 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

23% less funds holding

Funds holding: 122 → 94 (-28)

33% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 36

45% less capital invested

Capital invested by funds: $136M → $74.8M (-$61.2M)

66% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 41

90% less call options, than puts

Call options by funds: $7K | Put options by funds: $69K

Holders
94
Holders Change
-28
Holders Change %
-22.95%
% of All Funds
1.48%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
24
Reduced
36
Closed
41
Calls
$7K
Puts
$69K
Net Calls
-$62K
Net Calls Change
+$103K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$9.44M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.73M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.46M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.13M
5
Prudential Financial
Prudential Financial
New Jersey
+$781K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$4.23M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.89M
3
Bank of America
Bank of America
North Carolina
-$3.19M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.63M
5
PPA
Parametric Portfolio Associates
Washington
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$466K -$547K -173,965 -51%
PP
27
PDT Partners
New York
$452K +$15.7K +4,985 +3%
GCP
28
GSA Capital Partners
United Kingdom
$438K +$265K +84,191 +113%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$342K -$8.13K -2,585 -2%
KCM
30
Kennedy Capital Management
Missouri
$336K +$383K +121,789 New
Fidelity Investments
31
Fidelity Investments
Massachusetts
$286K +$325K +103,423 +37,608%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$285K -$24.8K -7,893 -7%
Millennium Management
33
Millennium Management
New York
$275K -$4.23M -1,345,848 -93%
BCM
34
Bridgeway Capital Management
Texas
$272K +$310K +98,400 New
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$261K -$118K -37,400 -28%
SSA
36
Schonfeld Strategic Advisors
New York
$205K +$136K +43,200 +138%
HCA
37
Harbor Capital Advisors
Illinois
$186K -$50.5K -16,056 -19%
OQS
38
Occudo Quantitative Strategies
Florida
$185K -$223K -70,897 -51%
Victory Capital Management
39
Victory Capital Management
Texas
$181K +$1.21K +385 +0.5%
CSS
40
Cubist Systematic Strategies
Connecticut
$178K -$108K -34,294 -35%
PCM
41
Prelude Capital Management
New York
$148K +$54.7K +17,400 +48%
XT
42
XTX Topco
Cayman Islands
$129K +$85.1K +27,051 +137%
PPA
43
Parametric Portfolio Associates
Washington
$119K -$1.01M -321,603 -88%
Barclays
44
Barclays
United Kingdom
$111K -$27K -8,594 -18%
OC
45
Oppenheimer & Co
New York
$104K -$24.2K -7,700 -17%
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$102K +$1.57K +500 +1%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$97K -$9.22K -2,932 -8%
LPL Financial
48
LPL Financial
California
$95K +$108K +34,285 New
PAG
49
Private Advisor Group
New Jersey
$93K +$71.1K +22,608 +205%
MAM
50
Marquette Asset Management
Minnesota
$92K +$41.8K +13,283 +66%
1
2
3 4 5

TCRR Hedge Fund Activity: Q1 2022 in Review

94 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2022, worth a combined $74.8M — down 45% from $136M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of TCRR and 14 opened new positions — a net loss of 27 holders — while 36 trimmed existing stakes and 24 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $9.44M. The largest seller was Millennium Management, cutting an estimated $4.23M.

  • 94 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2022, down from 122 in Q4 2021.
  • Funds reported $74.8M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2022, down 45% quarter-over-quarter.
  • 14 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2022 and 41 closed out, a net change of -27 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2022 was Tang Capital Management, an estimated $9.44M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q1 2022 was Millennium Management, an estimated $4.23M sold.

Based on aggregated 13F filings for Q1 2022.